What is PBM's health score?

PSYENCE BIOMEDICAL LTD. (PBM) has a TradeApes health score of 51 out of 100, rated Mixed. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is PBM's estimated fair value?

Based on our 5-year discounted cash flow model, PSYENCE BIOMEDICAL LTD.'s estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is PBM undervalued or overvalued?

Our model currently rates PBM as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for PBM... Refresh in a moment for the full analysis.

PSYENCE BIOMEDICAL LTD. (PBM)

Healthcare Inconclusive inconclusive mixed

$3.51

Updated: 2026-06-06

TradeApes Score

Financial Strength

30 Weak

Operating Trend

50 Mixed

Relative Value

60 Healthy

Capital Allocation

50 Mixed

Risk

80 Strong

Key Findings

+ Historically cheap — EV/EBITDA in bottom 25% of its 5-year range

Unlock Full Report →

− Weak interest coverage — earnings barely cover debt service

Unlock Full Report →

4 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.